Clinical Trial Matcher

NCT05960864

Chinese Spondyloarthritis Inception Cohort (CESPIC)

Not Yet Recruiting · Not specified · Southwest Hospital, China · registry updated 2024-04-17

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

Inclusion

  • Crohn's disease. Acute anterior uveitis. Psoriatic arthritis with axial involvement. Reactive arthritis.

Exclusion

  • Infections, Malignancies, Major cardiovascular events, Lower intestinal perforations Other adverse events

Open NCT05960864 on ClinicalTrials.govAll conditions

Chinese Spondyloarthritis Inception Cohort (CESPIC) | Clinical Trial Matcher